This page shows the SEC filing summaries for AC Immune SA.
AC Immune SA
CIK: 1651625 · 1 filing tracked
Filing History
1
20-F
Annual Report
March 13, 2026
- New collaboration with Takeda Pharmaceuticals in early 2024 for an Anti-Abeta Active Immunotherapy, including an upfront payment and potential future milestones.
- Proprietary SupraAntigen™ and Morphomer™ technology platforms for targeted neurodegenerative disease treatments and diagnostics.
- Solid cash position of CHF 85.0 million as of December 31, 2023, providing a projected cash runway until mid-2025.
Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.